Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Pfizer”

Resolution of Sickle Cell Leg Ulcers With VoxelotorTerminated
NCT05561140Phase 3Updated Jul 9, 2025
Sponsor: Pfizer
Sickle Cell Disease · Leg Ulcers
Brazil, Kenya, Nigeria
Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLCCompleted
NCT02039336Phase 1, Phase 2Updated Jul 8, 2025
Sponsor: The Netherlands Cancer Institute
Colorectal Cancer
Netherlands
Heat Wrap Device Safety With Age and Body FatCompleted
NCT01355653NAUpdated Jul 2, 2025
Sponsor: Pfizer
Back Pain
United States
Ibrance Real World InsightsCompleted
NCT03159195N/AUpdated Jul 1, 2025
Sponsor: Pfizer
Malignant Neoplasm of Breast
United States
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.Completed
NCT06307457N/AUpdated Jun 29, 2025
Sponsor: Pfizer
Breast Cancer
Denmark
A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy AdultsCompleted
NCT06911788Phase 1Updated Jun 29, 2025
Sponsor: Pfizer
Healthy Participants
Netherlands
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and USCompleted
NCT06504524N/AUpdated Jun 27, 2025
Sponsor: Pfizer
Multiple Myeloma
United States, Germany
Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In TaiwanCompleted
NCT02924584N/AUpdated Jun 26, 2025
Sponsor: Pfizer
ER/PR(+), Her2(-) Breast Cancer
Taiwan
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast CancerApproved For Marketing
NCT04220203N/AUpdated Jun 26, 2025
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
HER2-positive Breast Cancer
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer PatientsRecruiting
NCT06987734Phase 2Updated Jun 26, 2025
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer (NSCLC)
China
A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy AdultsCompleted
NCT06003777Phase 1Updated Jun 24, 2025
Sponsor: Pfizer
Healthy Participants
United States
Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South KoreaCompleted
NCT05132101N/AUpdated Jun 19, 2025
Sponsor: Pfizer
Metastatic Breast Cancer
South Korea
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)Completed
NCT03885089N/AUpdated Jun 19, 2025
Sponsor: Pfizer
Psoriasis Vulgaris · Psoriasis Arthropathica · Pustular Psoriasis · Erythrodermic Psoriasis
Japan
Healthcare Disparities in Alopecia AreataCompleted
NCT05727306N/AUpdated Jun 18, 2025
Sponsor: Momentum Data
Alopecia Areata
United Kingdom
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)Available
NCT05650476N/AUpdated Jun 12, 2025
Sponsor: Pfizer
Metastatic Castration-Resistant Prostate Cancer
Study Evaluating On-Demand Treatment Of Xyntha In Chinese SubjectsCompleted
NCT00868530Phase 3Updated Jun 12, 2025
Sponsor: Pfizer
Hemophilia A
China
A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.Completed
NCT05767905Phase 1Updated Jun 12, 2025
Sponsor: Pfizer
Healthy
United States
Phase 2 Study of Dacomitinib in NSCLCActive Not Recruiting
NCT04027647Phase 2Updated Jun 12, 2025
Sponsor: National Cancer Centre, Singapore
NSCLC Stage IIIB · NSCLC Stage IIIC · NSCLC Stage IV · Recurrent NSCLC
Hong Kong, Malaysia, Singapore, South Korea, Thailand
PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and OlderCompleted
NCT04613375N/AUpdated Jun 11, 2025
Sponsor: Pfizer
Community Acquired Pneumonia (CAP)
Spain
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung CancerCompleted
NCT04362072Phase 4Updated Jun 11, 2025
Sponsor: Pfizer
Carcinoma · Non-Small-Cell Lung
United States, India, Italy, Poland, Spain +2 more
Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet FormulationCompleted
NCT05263895Phase 1Updated Jun 11, 2025
Sponsor: Pfizer
Bioavailability
United States
The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort StudyCompleted
NCT03835780N/AUpdated Jun 11, 2025
Sponsor: Momentum Data
Venous Thromboses · Venous Thromboembolism · Deep Vein Thrombosis · Pulmonary Embolism
United Kingdom
Sirolimus for Cowden Syndrome With Colon PolyposisCompleted
NCT04094675Phase 2Updated Jun 10, 2025
Sponsor: Ohio State University
PTEN Gene Mutation · PTEN Hamartoma Tumor Syndrome · PTEN Hamartoma Syndrome · Cowden Syndrome
United States
Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid ArthritisCompleted
NCT05572567N/AUpdated Jun 8, 2025
Sponsor: Pfizer
Arthritis, Rheumatoid
Japan
Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis PatientsCompleted
NCT04079920N/AUpdated Jun 8, 2025
Sponsor: Pfizer
Rheumatoid Arthritis
Greece

Previous page Next page